Baxter International Inc., of Deerfield, Ill., named John Orloff vice president and global head of research and development for Baxter Bioscience.

Coherus Biosciences Inc., of Redwood City, Calif., added Bryan Lawlis to its board.

Forum Pharmaceuticals Inc., of Boston, named Christine Boisclair vice president, regulatory affairs.

Glycomimetics Inc., of Gaithersburg, Md., added Mark A. Goldberg to its board.

Intezyne Technologies Inc., of Tampa, Fla., appointed Carolyn M. Paradise acting chief medical officer, and Tim Coan chief financial officer.

Jounce Therapeutics Inc., of Cambridge, Mass., named Richard Murray CEO and Cary Pfeffer, chairman of its board. Pfeffer has been serving as interim CEO.

Neostem Inc., of New York, added Steven M. Klosk to its board.

Nuevolution AS, of Copenhagen, appointed Paul Workman scientific advisor.

Oxford Biotherapeutics Ltd., of Oxford, UK, appointed Eugen Leo head of clinical development.

Strand Life Sciences, of Bangalore, India, appointed Scott Storrer president of North America. He will oversee strategy, expansion and operation of Strand Genomics Inc., a wholly owned subsidiary.

Vitae Pharmaceuticals Inc., of Fort Washington, Pa., appointed Art Fratamico chief business officer and Richard Morris chief financial officer.